Tyrosine kinase inhibitors - Open Access .click

Results 321 to 330 of about 457,600 (353)

Some of the next articles are maybe not open access.

Imatinib: a selective tyrosine kinase inhibitor

European Journal of Cancer, 2002
The understanding of the pathophysiology of a large number of cancer types provides a strategy to target cancer cells with minimal effect on normal cells. Protein phosphorylation and dephosphorylation play a pivotal role in intracellular signaling; to regulate signal transduction pathways, there are approximately 700 protein kinases and 100 protein ...
P W, Manley +7 more
openaire +2 more sources

HER-Targeted Tyrosine-Kinase Inhibitors

Oncology, 2002
Improved understanding of tumor biology has led to the identification of numerous growth factors that are involved in malignant transformation and tumor progression. Many of these factors induce cellular responses through receptors with intrinsic tyrosine kinase (TK) activity. Therefore, inhibiting receptor TK activity is a way to effectively block the
José, Baselga, Lisa A, Hammond
openaire +2 more sources

Tyrosine kinase inhibitors: A clinical perspective

Current Oncology Reports, 2002
Cancer treatment has so far been restricted to cytotoxic and hormonal agents. These have been of limited value in their efficacy and their toxicity profile. A new era of targeted therapies is rapidly evolving. A key target being actively pursued is the receptor tyrosine kinase.
Sanjay, Goel, Sridhar, Mani, Roman, Perez-Soler +2 more
openaire +2 more sources

Tyrosine-Kinase Inhibitors